医学
肝硬化
胃肠病学
内科学
瞬态弹性成像
纤维化
临床终点
安慰剂
肝活检
脂肪变性
代理终结点
脂肪性肝炎
肝病
肝纤维化
脂肪肝
随机对照试验
活检
病理
疾病
替代医学
作者
Rohit Loomba,Mazen Noureddin,Kris V. Kowdley,Anita Kohli,Aasim Sheikh,Guy Neff,Bal Raj Bhandari,Nadege Gunn,Stephen H. Caldwell,Zachary Goodman,Ilan Wapinski,Murray B. Resnick,Andrew H. Beck,Dora Ding,Catherine Jia,Jen‐Chieh Chuang,Ryan S. Huss,Chuhan Chung,G. Mani Subramanian,Robert P. Myers
出处
期刊：Hepatology
[Lippincott Williams & Wilkins]
日期：2020-11-10
卷期号：73 (2): 625-643
被引量：261
摘要
In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
无极微光
鸟兽兽
WTKKKL
tiptip
乐空思
lizishu
蓝天
Semy
pluto
手机
嘉心糖
干净的琦
Criminology34
乐观秋荷
pcr163
SuiWu
邓佳鑫Alan
贪玩的秋柔
学术文献互助
皖公网安备34019202002308